MENU
+Compare
LXRX
Stock ticker: NASDAQ
AS OF
Aug 11, 03:18 PM (EDT)
Price
$1.04
Change
-$0.04 (-3.70%)
Capitalization
392.47M

LXRX Lexicon Pharmaceuticals Forecast, Technical & Fundamental Analysis

Lexicon Pharmaceuticals Inc is a biopharmaceutical company... Show more

Industry: #Biotechnology
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for LXRX with price predictions
Aug 08, 2025

LXRX in +17.39% Uptrend, growing for three consecutive days on July 17, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where LXRX advanced for three days, in of 216 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 66 cases where LXRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The 50-day moving average for LXRX moved above the 200-day moving average on July 28, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

The Aroon Indicator entered an Uptrend today. In of 144 cases where LXRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for LXRX moved out of overbought territory on July 18, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on July 28, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on LXRX as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for LXRX turned negative on July 24, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LXRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

LXRX broke above its upper Bollinger Band on July 16, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.032) is normal, around the industry mean (18.662). P/E Ratio (0.000) is within average values for comparable stocks, (54.033). LXRX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.909). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (6.698) is also within normal values, averaging (286.048).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

LXRX is expected to report earnings to fall 750.00% to -6 cents per share on October 30

Lexicon Pharmaceuticals LXRX Stock Earnings Reports
Q3'25
Est.
$-0.06
Q2'25
Beat
by $0.10
Q1'25
Beat
by $0.05
Q4'24
Beat
by $0.03
Q3'24
Missed
by $0.02
The last earnings report on August 06 showed earnings per share of 0 cents, beating the estimate of -9 cents. With 1.01M shares outstanding, the current market capitalization sits at 392.47M.
A.I. Advisor
published General Information

General Information

a company, which engages in discovery and development of breakthrough treatments for human disease

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
2445 Technology Forest Boulevard
Phone
+1 281 863-3000
Employees
285
Web
https://www.lexpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PREFX83.220.47
+0.57%
T. Rowe Price Tax-Efficient Equity
FEYTX28.930.12
+0.42%
Fidelity Advisor Asset Manager 85% M
SEPIX12.940.01
+0.08%
Saratoga Energy & Basic Materials I
TVIRX79.22-0.01
-0.01%
Thornburg Small/Mid Cap Core R4
IRGTX10.13-0.04
-0.39%
VY® CBRE Global Real Estate S

LXRX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, LXRX has been loosely correlated with OCUL. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if LXRX jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXRX
1D Price
Change %
LXRX100%
-3.57%
OCUL - LXRX
39%
Loosely correlated
-0.73%
PLRX - LXRX
38%
Loosely correlated
-1.19%
RAPP - LXRX
35%
Loosely correlated
-5.58%
TECH - LXRX
34%
Loosely correlated
+0.54%
EPIX - LXRX
34%
Loosely correlated
+0.53%
More